{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To investigate change in plasma matrix metalloproteinase 9 (MMP9) levels as a biomarker of treatment response; to assess plasma matrix metalloproteinase 9 (MMP9) expression by immunohistochemistry (IHC) and correlate to response in order to test the hypothesis that elevated intratumoral levels of plasma matrix metalloproteinase 9 (MMP9) can predict response to doxycycline. To assess activation/expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kb) and Signal transducer and activator of transcription 3 (STAT 3) pathways in archived tumor by immunohistochemistry (IHC) to predict response or resistance to doxycycline.","groups":[{"description":"Doxycycline 200 mg twice daily\n\nDoxycycline","id":"OG000","title":"Doxycycline"}],"populationDescription":"No data displayed because Outcome Measure has zero total participants analyzed","reportingStatus":"POSTED","timeFrame":"One year","title":"Exploratory Objective","type":"OTHER_PRE_SPECIFIED"}